‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
admin The biopharmaceutical sector witnessed a dynamic period marked by significant clinical advancements, strategic corporate maneuvers,...
drug development
Latigo Biotherapeutics Secures $345.6 Million in Landmark IPO, Poised to Challenge Giants in Non-Opioid Pain Market Amidst Biotech Resurgence
Pain drugmaker Latigo Biotherapeutics successfully completed its initial public offering (IPO) on Thursday, August 7,...
Dr. Erica Schwartz Confirmed as CDC Director Amidst Deep-Seated Challenges and Public Health Turmoil
Dr. Erica Schwartz has been confirmed as the next director of the Centers for Disease...
Tarsus Pharmaceuticals Acquires Alkeus Pharmaceuticals in Up to $800 Million Deal, Advancing Stargardt Disease Treatment
Tarsus Pharmaceuticals, a prominent developer of treatments across ophthalmology, dermatology, and infectious diseases, has announced...
FDA Grants Accelerated Approval to Replimune’s Tudriqev for Advanced Melanoma After Contentious Review Process
The U.S. Food and Drug Administration (FDA) has officially granted accelerated approval to Replimune’s novel...
FDA Approves Orzeyful, a Groundbreaking Orexin-2 Agonist, Ushering in a New Era for Narcolepsy Type 1 Treatment
The U.S. Food and Drug Administration (FDA) has granted approval to Orzeyful, a novel medicine...
FDA Approves Moderna’s mFlusiva, Marking a Landmark Entry for mRNA Technology into Seasonal Flu Vaccination
The U.S. Food and Drug Administration (FDA) has granted approval for mFlusiva, previously known as...
Braveheart Bio Spearheads Biotech IPO Surge, As Five Firms Secure Over $1 Billion in Public Offerings This Week
Braveheart Bio, a rapidly emerging biotechnology company focused on cardiovascular therapies, has successfully completed its...
Novo Nordisk Faces Setbacks as Eli Lilly’s Injectable Franchise Continues to Outperform in Fierce GLP-1 Market
The intense rivalry between pharmaceutical giants Novo Nordisk and Eli Lilly in the burgeoning market...
Attovia Therapeutics Secures $289 Million in Upsized IPO, Signifying Robust Biotech Market Recovery
Attovia Therapeutics, a burgeoning biotechnology firm focused on innovative antibody-drug technologies for skin disorders and...
